Enhanced attenuation of chikungunya vaccines expressing antiviral cytokines | npj Vaccines – Nature.com

Levi, L. I. & Vignuzzi, M. Arthritogenic Alphaviruses: A Worldwide Emerging Threat? Microorganisms 7, 133 (2019).

Article CAS PubMed PubMed Central Google Scholar

Organization, W. H. Chikungunya Fact Sheet, (2021).

PAHO. (World Health Organization, Pan American Health Organization, 2015).

Chikungunya Cases by Country or Territory. (2023).

Shocket, M. S., Ryan, S. J. & Mordecai, E. A. Temperature explains broad patterns of Ross River virus transmission. Elife 7, e37762 (2018).

Article PubMed PubMed Central Google Scholar

Murphy, A. K. et al. Spatial and temporal patterns of Ross River virus in south east Queensland, Australia: identification of hot spots at the rural-urban interface. BMC Infect. Dis. 20, 722 (2020).

Article PubMed PubMed Central Google Scholar

Serra, O. P., Cardoso, B. F., Ribeiro, A. L., Santos, F. A. & Slhessarenko, R. D. Mayaro virus and dengue virus 1 and 4 natural infection in culicids from Cuiaba, state of Mato Grosso, Brazil. Mem. Inst. Oswaldo Cruz 111, 2029 (2016).

Article CAS PubMed PubMed Central Google Scholar

Vieira, C. J. et al. Detection of Mayaro virus infections during a dengue outbreak in Mato Grosso, Brazil. Acta Trop. 147, 1216 (2015).

Article PubMed Google Scholar

Caicedo, E. Y. et al. Correction: The epidemiology of Mayaro virus in the Americas: A systematic review and key parameter estimates for outbreak modelling. PLoS Negl. Trop. Dis. 17, e0011034 (2023).

Article PubMed PubMed Central Google Scholar

Larrieu, S. et al. Factors associated with persistence of arthralgia among Chikungunya virus-infected travellers: report of 42 French cases. J. Clin. Virol. 47, 8588 (2010).

Article PubMed Google Scholar

Borgherini, G. et al. Persistent arthralgia associated with chikungunya virus: a study of 88 adult patients on reunion island. Clin. Infect. Dis. 47, 469475 (2008).

Article PubMed Google Scholar

Soumahoro, M. K. et al. Impact of Chikungunya virus infection on health status and quality of life: a retrospective cohort study. PLoS One 4, e7800 (2009).

Article ADS PubMed PubMed Central Google Scholar

Sissoko, D. et al. Post-epidemic Chikungunya disease on Reunion Island: course of rheumatic manifestations and associated factors over a 15-month period. PLoS Negl. Trop. Dis. 3, e389 (2009).

Article PubMed PubMed Central Google Scholar

Couturier, E. et al. Impaired quality of life after chikungunya virus infection: a 2-year follow-up study. Rheumatol. (Oxf.) 51, 13151322 (2012).

Article Google Scholar

Soumahoro, M. K. et al. The Chikungunya epidemic on La Reunion Island in 2005-2006: a cost-of-illness study. PLoS Negl. Trop. Dis. 5, e1197 (2011).

Article PubMed PubMed Central Google Scholar

Alvis-Zakzuk, N. J. et al. Economic Costs of Chikungunya Virus in Colombia. Value Health Reg. Issues 17, 3237 (2018).

Article PubMed Google Scholar

Staikowsky, F. et al. Retrospective survey of Chikungunya disease in Reunion Island hospital staff. Epidemiol. Infect. 136, 196206 (2008).

Article CAS PubMed Google Scholar

Harrison, V. R., Eckels, K. H., Bartelloni, P. J. & Hampton, C. Production and Evaluation of a Formalin-Killed CHIKV vaccine. J. Immunol. 107, 643647 (1971).

Article CAS PubMed Google Scholar

Metz, S. W. & Pijlman, G. P. Production of Chikungunya Virus-Like Particles and Subunit Vaccines in Insect Cells. Methods Mol. Biol. 1426, 297309 (2016).

Article CAS PubMed Google Scholar

Khan, M., Dhanwani, R., Rao, P. V. & Parida, M. Subunit vaccine formulations based on recombinant envelope proteins of Chikungunya virus elicit balanced Th1/Th2 response and virus-neutralizing antibodies in mice. Virus Res. 167, 236246 (2012).

Article CAS PubMed Google Scholar

Chang, L. J. et al. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet 384, 20462052 (2014).

Article CAS PubMed Google Scholar

Chen, G. L. et al. Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial. JAMA 323, 13691377 (2020).

Article CAS PubMed PubMed Central Google Scholar

Ramsauer, K. et al. Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect. Dis. 15, 519527 (2015).

Article CAS PubMed Google Scholar

Folegatti, P. M. et al. A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial. Nat. Commun. 12, 4636 (2021).

Article ADS CAS PubMed PubMed Central Google Scholar

August, A. et al. A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus. Nat. Med. 27, 22242233 (2021).

Article CAS PubMed PubMed Central Google Scholar

Norrby, E. Yellow fever and Max Theiler: the only Nobel Prize for a virus vaccine. J. Exp. Med. 204, 27792784 (2007).

Article CAS PubMed PubMed Central Google Scholar

Matrajt, L., Britton, T., Halloran, M. E. & Longini, I. M. Jr One versus two doses: What is the best use of vaccine in an influenza pandemic? Epidemics 13, 1727 (2015).

Article PubMed PubMed Central Google Scholar

Barnabas, R. V. & Wald, A. A Public Health COVID-19 Vaccination Strategy to Maximize the Health Gains for Every Single Vaccine Dose. Ann. Intern. Med. 174, 552553 (2021).

Article PubMed Google Scholar

Burger, E. A., Campos, N. G., Sy, S., Regan, C. & Kim, J. J. Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country. Vaccine 36, 48234829 (2018).

Article PubMed PubMed Central Google Scholar

Levitt, N. H. et al. Development of an attenuated strain of chikungunya virus for use in vaccine production. Vaccine 4, 157162 (1986).

Article CAS PubMed Google Scholar

Gorchakov, R. et al. Attenuation of Chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein. J. Virol. 86, 60846096 (2012).

Article CAS PubMed PubMed Central Google Scholar

Ly H. Ixchiq (VLA1553): The first FDA-approved vaccine to prevent disease caused by Chikungunya virus infection. Virulence. 15, 2301573 (2024)

Hallengard, D. et al. Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice. J. Virol. 88, 28582866 (2014).

Article PubMed PubMed Central Google Scholar

Roques, P. et al. Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus. JCI Insight 2, e83527 (2017).

Article PubMed PubMed Central Google Scholar

Wressnigg, N. et al. Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial. Lancet Infect. Dis. 20, 11931203 (2020).

Article PubMed Google Scholar

Valneva. (ed Valneva Austria GmbH) (2021).

McMahon, R. et al. A randomized, double-blinded phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults. J. Travel Med. 13, taad156 (2023).

Google Scholar

Weger-Lucarelli, J., Aliota, M. T., Kamlangdee, A. & Osorio, J. E. Identifying the Role of E2 Domains on Alphavirus Neutralization and Protective Immune Responses. PLoS Negl. Trop. Dis. 9, e0004163 (2015).

Article PubMed PubMed Central Google Scholar

Weger-Lucarelli, J. et al. Dissecting the Role of E2 Protein Domains in Alphavirus Pathogenicity. J. Virol. 90, 24182433 (2015).

Article PubMed Google Scholar

Capitini, C. M., Fry, T. J. & Mackall, C. L. Cytokines as Adjuvants for Vaccine and Cellular Therapies for Cancer. Am. J. Immunol. 5, 6583 (2009).

Article CAS PubMed PubMed Central Google Scholar

Pennslyvania, U. o. PENNVAX-B With or Without IL-12 or IL-15 as a DNA Vaccine for HIV Infection. (2016).

NIAID. Safety of and Immune Response to an HIV Preventive Vaccine (HIV-1 Gag DNA Alone or With IL-15 DNA) Given With or Without Different Booster Vaccinations in HIV Uninfected Adults. (2021).

Chen, T. et al. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy. J. Immunother. Cancer 9, e001647 (2021).

Article PubMed PubMed Central Google Scholar

Li, M. Safety of Recombinant Human IL-21 Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors. (2023).

Nordisk, N. Efficacy Study of IL-21 to Treat Metastatic Melanoma. (2004).

Squibb, B. M. (2015).

Clinic, M. Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients with Multiple Myeloma. (2011).

Inc, B. IMLYGIC, https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/imlygic. (2021).

Gherardi, M. M. et al. IL-12 Delivery from Recombinant Vaccinia Virus Attenuates the Vector and Enhances the Cellular Immune Response Against HIV-1 Env in a Dose-Dependent Manner. J. Immunol. 162, 67246733 (1999).

Article CAS PubMed Google Scholar

Abaitua, F., Rodriguez, J. R., Garzon, A., Rodriguez, D. & Esteban, M. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma. Virus Res. 116, 1120 (2006).

Article CAS PubMed Google Scholar

Jarasch, N. et al. Interferon-gamma-induced activation of nitric oxide-mediated antiviral activity of macrophages caused by a recombinant coxsackievirus B3. Viral Immunol. 18, 355364 (2005).

Article CAS PubMed Google Scholar

Spolski, R. & Leonard, W. J. Interleukin-21: a double-edged sword with therapeutic potential. Nat. Rev. Drug Discov. 13, 379395 (2014).

Article CAS PubMed Google Scholar

Lee, A. J. & Ashkar, A. A. The Dual Nature of Type I and Type II Interferons. Front Immunol. 9, 2061 (2018).

Article PubMed PubMed Central Google Scholar

Gardner, J. et al. Chikungunya virus arthritis in adult wild-type mice. J. Virol. 84, 80218032 (2010).

Article CAS PubMed PubMed Central Google Scholar

Morrison, T. E. et al. A mouse model of chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence. Am. J. Pathol. 178, 3240 (2011).

Article CAS PubMed PubMed Central Google Scholar

Lentscher, A. J. et al. Chikungunya virus replication in skeletal muscle cells is required for disease development. J. Clin. Invest. 130, 14661478 (2020).

Article CAS PubMed PubMed Central Google Scholar

View post:

Enhanced attenuation of chikungunya vaccines expressing antiviral cytokines | npj Vaccines - Nature.com